Inactivation of human immunodeficiency virus type 1 by porphyrins

被引:91
|
作者
Vzorov, AN
Dixon, DW
Trommel, JS
Marzilli, LG
Compans, RW [1 ]
机构
[1] Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Chem, Atlanta, GA 30322 USA
[3] Georgia State Univ, Dept Chem, Atlanta, GA 30333 USA
关键词
D O I
10.1128/AAC.46.12.3917-3925.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have evaluated the anti-human immunodeficiency virus (HIV) activity of a series of natural and synthetic porphyrins to identify compounds that could potentially be used as microbicides to provide a defense against infection by sexually transmitted virus. For assays we used an epithelial HeLa-CD4 cell line with an integrated long terminal repeat-p-galactosidase gene. For structure-activity analysis, we divided the porphyrins tested into three classes: (i) natural porphyrins, (ii) metallo-tetraphenylporphyrin tetrasulfonate (metallo-TPPS4) derivatives, and (iii) sulfonated tetra-arylporphyrin derivatives. None of the natural porphyrins studied reduced infection by more than 80% at a concentration of 5 mug/ml in these assays. Some metal chelates of TPPS4 were more active, and a number of sulfonated tetra-aryl derivatives showed significantly higher activity. Some of the most active compounds were the sulfonated tetranaphthyl porphyrin (TNapPS), sulfonated tetra-anthracenyl porphyrin (TAnthPS), and sulfonated 2,6-difluoro-meso-tetraphenylporphine [TPP(2,6-F2)S] and its copper chelate [TPP(2,6-F2)S,Cu], which reduced infection by 99, 96, 94, and 96%, respectively. Our observations indicate that at least some of these compounds are virucidal, i.e., that they render the virus noninfectious. The active compounds were found to inhibit binding of the HIV type 1 gp120 to CD4 and also to completely inhibit the ability of Env proteins expressed from recombinant vectors to induce cell fusion with receptor-bearing target cells. These results support the conclusion that modified porphyrins exhibit substantial activity against HIV and that their target is the HIV Env protein.
引用
收藏
页码:3917 / 3925
页数:9
相关论文
共 50 条
  • [21] INACTIVATION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) BY ULTRAVIOLET AND X-IRRADIATION
    HENDERSON, EE
    TUDOR, G
    YANG, JY
    RADIATION RESEARCH, 1992, 131 (02) : 169 - 176
  • [22] Genetic drift of human immunodeficiency virus type 1?
    Holmes, EC
    Zanotto, PMD
    JOURNAL OF VIROLOGY, 1998, 72 (01) : 886 - 887
  • [23] THE LIVER AND THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1
    LESUR, G
    SAVEUSE, H
    CHETRIT, B
    LEBOURGEOIS, P
    ROUVEIX, E
    DORRA, M
    ANNALES DE MEDECINE INTERNE, 1991, 142 (03): : 219 - 225
  • [24] Vasectomy and human immunodeficiency virus type 1 in semen
    Krieger, JN
    Nirapathpongporn, A
    Chaiyaporn, M
    Peterson, G
    Nikolaeva, I
    Akridge, R
    Ross, SO
    Coombs, RW
    JOURNAL OF UROLOGY, 1998, 159 (03): : 820 - 825
  • [25] Human immunodeficiency virus type 1 subtypes in Oman
    Al Dhahry, SHS
    Merigan, TC
    Scrimgeour, E
    Al Suwaid, A
    Al Lawati, MRM
    El Khatim, HS
    Al Kobaisi, MF
    JOURNAL OF CLINICAL VIROLOGY, 2003, 28 : S73 - S73
  • [26] Human immunodeficiency virus type 1 divergent variants
    Plantier, J. -C.
    Simon, F.
    JOURNAL DES ANTI-INFECTIEUX, 2011, 13 (03) : 170 - 183
  • [27] Human immunodeficiency virus type 1 impairs sumoylation
    Mete, Bilgul
    Pekbilir, Emre
    Bilge, Bilge Nur
    Georgiadou, Panagiota
    Celik, Elif
    Sutlu, Tolga
    Tabak, Fehmi
    Sahin, Umut
    LIFE SCIENCE ALLIANCE, 2022, 5 (06)
  • [28] Organization of immature human immunodeficiency virus type 1
    Wilk, T
    Gross, I
    Gowen, BE
    Rutten, T
    de Haas, F
    Welker, R
    Kräusslich, HG
    Boulanger, P
    Fuller, SD
    JOURNAL OF VIROLOGY, 2001, 75 (02) : 759 - 771
  • [29] Human immunodeficiency virus type 1 protease inhibitors
    McDonald, CK
    Kuritzkes, DR
    ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (09) : 951 - 959
  • [30] Primary human immunodeficiency virus type 1 infection
    Soogoor M.
    Daar E.S.
    Current HIV/AIDS Reports, 2005, 2 (2) : 55 - 60